You can now submit a Letter of Intent at any time, as the application process has shifted to a rolling deadline. Funding amounts and project durations are now fully negotiable, removing the previous $3 million, three-year cap. Additionally, the program's scope has broadened to support general therapeutics and devices for type 1 diabetes, rather than focusing specifically on cardiovascular disease.
Funder: Breakthrough T1D
Due Dates: Rolling (LOIs accepted year-round; by invitation or RFA)
Funding Amounts: No set maximum; typically requires company matching funds equal to or greater than Breakthrough T1D’s contribution; duration and amount are negotiated per project.
Summary: Supports for-profit companies to advance research, development, and commercialization of therapies or devices for type 1 diabetes aligned with Breakthrough T1D priorities.
Key Information: Applicants must commit matching funds and contact Breakthrough T1D staff before submitting a Letter of Intent.